Champions Biotechnology, Inc.'s Doug Burkett, PhD, to Present at BIO CEO & Investor Conference
February 05 2009 - 8:22AM
PR Newswire (US)
Waldorf Astoria Hotel in New York City, Tuesday, February 10th 2009
ARLINGTON, Va., Feb. 5 /PRNewswire-FirstCall/ -- Doug Burkett, PhD,
Principal Executive Officer of Champions Biotechnology, Inc. (OTC
Bulletin Board: CSBR), a company engaged in the development of
advanced preclinical platforms and tumor specific data to enhance
the value of oncology drugs, will present at BIO CEO & Investor
Conference Tuesday, February 10, 2009 at the Waldorf Astoria Hotel
in New York City. The presentation will be held at 10:30am in the
Jade Room. Dr. Burkett's presentation will focus on Champions'
developing pipeline of value enhanced oncology drugs. Dr. Burkett
will also highlight the company's Biomerk Tumorgraft(TM) platform,
which pre-qualifies its pipeline to be those oncology drug
candidates that offer the best opportunity, either singularly or in
combination, for clinical success. About Champions Biotechnology,
Inc. Champions Biotechnology, Inc. is engaged in the development of
advanced preclinical platforms and predictive tumor specific data
to enhance and accelerate the value of oncology drugs. The
Company's Preclinical Platform is a novel approach based upon the
implantation of primary human tumors in immune deficient mice
followed by propagation of the resulting engraftments (Biomerk
Tumorgrafts(TM)) in a manner that preserves the biological
characteristics of the original human tumor. Early studies suggest
that unlike traditional xenografts these Tumorgrafts closely
reflect human cancer biology and their response to drugs is
predictive of clinical outcomes in cancer patients. Champions
Biotechnology leverages its preclinical platform to evaluate drug
candidates and to develop a portfolio of novel therapeutic
candidates through pre-clinical trials. As drugs progress through
this early stage of development, the Company plans to sell, partner
or license them to pharmaceutical and/or biotechnology companies,
as appropriate. The Company also offers its predictive preclinical
platform and tumor specific data to physicians for personalized
patient care and to companies for evaluation of oncology drugs in
models that integrate prognostic testing with biomarker discovery.
Forward-Looking Statements This press release contains
"forward-looking statements" (within the meaning of the Private
Securities Litigation Act of 1995) that inherently involve risk and
uncertainties. Champions Biotechnology generally uses words such as
"believe," "may," "could," "will," "intend," "expect,"
"anticipate," "plan," and similar expressions to identify
forward-looking statements. One should not place undue reliance on
these forward-looking statements. The Company's actual results
could differ materially from those anticipated in the
forward-looking statements for many unforeseen factors. See
Champions Biotechnology's Form 10-KSB for the fiscal year ended
April 30, 2008 for a discussion of such risks, uncertainties and
other factors. Although the Company believes the expectations
reflected in the forward-looking statements are reasonable, they
relate only to events as of the date on which the statements are
made, and Champions Biotechnology's future results, levels of
activity, performance or achievements, including but not limited to
the achievement of milestones as required to realize the royalties
referenced above, may not meet these expectations. The Company does
not intend to update any of the forward-looking statements after
the date of this press release to conform these statements to
actual results or to changes in Champions Biotechnology's
expectations, except as required by law. DATASOURCE: Champions
Biotechnology, Inc. CONTACT: James Carbonara, Susan Morgenbesser or
Janet Vasquez, +1-212-825-3210, all of The Investor Relations
Group, Inc. for Champions Biotechnology
Copyright